- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00397475
Evaluation of Colecalciferol Substitution in Dialysis Patients
May 26, 2015 updated by: University Hospital, Saarland
The purpose of this study is to determine the effect of a colecalciferol substitution in dialysis patients on bone metabolism and immune system
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Saarland
-
Homburg, Saarland, Germany, 66421
- University Hospital of Saarland, Dpt. of Internal Medicine IV, Div. of Nephrology and Hypertension
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Serum 25-OH-Vit.D-levels < 60 ng/ml
- Age > 18 years
- dialysis treatment > 3 Months
- signed written informed consent
- Serum-Calcium-levels < 2,6 mmol/l within the last 4 weeks
- Serum-Phosphate-levels < 7,0 mg/dl within the last 4 weeks
- Ca x P-Product < 75 mg2/dl2 within the last 4 weeks
Exclusion Criteria:
- Serum 25-OH-Vit.-D-levels > 60 ng/ml
- concommitant participation in another interventional trial
- psychiatric disorders preventing from valid informed consent
- Hyperphosphatemia (> 7,0 mg/dl) within the last 4 weeks
- Hypercalcemia (> 2,6 mmol/l) within the last 4 weeks
- Ca x P-Product > 75 mg2/dl2 within the last 4 weeks
- pregnancy or lactation
- known malignancy
- liver disease, defined as 2-fold upper limit of ASAT-, or ALAT-levels
- PTH levels < 50 pg/ml
- current clinically relevant infections treated with antibiotic therapy and raised hsCRP levels
- Chronic viral Infectious diseases (e.g. HIV, Hepatitis B or C)
- Immunosuppressant Medication
- known hematologic disorders, other than renal anemia
- age below 18 years
- known anaphylactic reaction against the study medication or other ingredients of the study drug preparation
- renal calculus
- Pseudohypoparathyroidism
- Medication including cardiac glycosides
- Sarkoidosis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
CD14/CD16-Monocyte-Subsets (Frequency)
|
Secondary Outcome Measures
Outcome Measure |
---|
Production of Cytokines: IFN-γ, TNF-α
|
Serum levels of Calcium, Phosphorus, iPTH, hsCRP, alkaline phosphatase
|
Th1/Th2- and Tc1/Tc2-Lymphocyte-Frequency
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Eric Seibert, M.D., University Hospital of Saarland, Dpt. of Internal Medicine IV, Div. of Nephrology and Hypertension
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2006
Study Completion (Actual)
March 1, 2007
Study Registration Dates
First Submitted
November 7, 2006
First Submitted That Met QC Criteria
November 7, 2006
First Posted (Estimate)
November 9, 2006
Study Record Updates
Last Update Posted (Estimate)
May 27, 2015
Last Update Submitted That Met QC Criteria
May 26, 2015
Last Verified
May 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Kidney Diseases
- Urologic Diseases
- Endocrine System Diseases
- Parathyroid Diseases
- Renal Insufficiency, Chronic
- Hyperparathyroidism
- Renal Insufficiency
- Hyperparathyroidism, Secondary
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Vitamin D
- Cholecalciferol
Other Study ID Numbers
- 142/06
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperparathyroidism, Secondary
-
The Second Hospital of Nanjing Medical UniversityRecruitingSecondary Hyperparathyroidism;ParathyroidectomyChina
-
Phramongkutklao College of Medicine and HospitalCompletedAlfacalcidol, Secondary Hyperparathyroidism, Hemodialysis
-
Chang Gung Memorial HospitalCompletedSecondary Hyperparathyroidism Due to Renal CausesTaiwan
-
Fundación SenefroAbbVie; Effice Servicios Para la Investigacion S.L.CompletedSecondary Hyperparathyroidism Due to Renal CausesSpain
-
Min-Sheng General HospitalTaipei Medical University; Taipei Medical University Shuang Ho Hospital; National... and other collaboratorsCompletedHyperparathyroidism; Secondary, RenalTaiwan
-
Shanghai Zhongshan HospitalUnknownHyperparathyroidism; Secondary, Renal
-
Shanghai Hengrui Pharmaceutical Co., Ltd.Active, not recruiting
-
Sanwa Kagaku Kenkyusho Co., Ltd.Completed
-
Sanwa Kagaku Kenkyusho Co., Ltd.CompletedSecondary HyperparathyroidismJapan
-
Deltanoid PharmaceuticalsCompletedSecondary HyperparathyroidismUnited States
Clinical Trials on Colecalciferol
-
University Medical Center GroningenNetherlands Foundation for Cardiovascular ExcellenceCompleted
-
Faculty Hospital Kralovske VinohradyBrno University Hospital; Nemocnice T.Bati, ZlinUnknown
-
Germans Trias i Pujol HospitalFundació Institut Germans Trias i Pujol; Spanish Clinical Research Network... and other collaboratorsCompletedUrothelial CarcinomaSpain
-
Medical University of GrazAustrian Science Fund (FWF)CompletedHealthy | Polycystic Ovary Syndrome | Vitamin D DeficiencyAustria
-
Federal University of Rio Grande do SulCompletedDeficiency, Vitamin DBrazil
-
National Institute of Allergy and Infectious Diseases...Department of Health and Human Services; HIV Vaccine Trials Network; Inovio Pharmaceuticals and other collaboratorsActive, not recruiting
-
Imperial College LondonWithdrawnCrohn's DiseaseUnited Kingdom
-
Radboud University Medical CenterUnknownHIV Infections | Vitamin D DeficiencyNetherlands
-
Amsterdam UMC, location VUmcRadboud University Medical Center; Leiden University Medical CenterCompletedChronic Obstructive Pulmonary DiseaseNetherlands
-
University of TurkuUnknownColecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)Multiple SclerosisFinland